Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Update

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 21,539 shares, an increase of 610.2% from the August 15th total of 3,033 shares. Based on an average daily volume of 885,605 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Emmaus Life Sciences Stock Performance

Shares of EMMA stock opened at $0.06 on Friday. The company has a market capitalization of $4.04 million, a price-to-earnings ratio of -0.64 and a beta of 10.07. Emmaus Life Sciences has a 52-week low of $0.01 and a 52-week high of $0.09. The company has a 50-day simple moving average of $0.03 and a two-hundred day simple moving average of $0.02.

Emmaus Life Sciences (OTCMKTS:EMMA) last posted its earnings results on Friday, August 14th. The company reported $0.02 EPS for the quarter. The firm had revenue of $6.32 million for the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.